Skandinaviska Enskilda Banken (SEB)’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-56,619
| Closed | -$43.7M | – | 581 |
|
|
2025
Q4 | $43.7M | Sell |
56,619
-355
| -0.6% | -$241K | 0.18% | 105 |
|
|
2025
Q3 | $32M | Sell |
56,974
-11,166
| -16% | -$6.31M | 0.13% | 133 |
|
|
2025
Q2 | $35.8M | Hold |
68,140
| – | – | 0.16% | 115 |
|
|
2025
Q1 | $43.2M | Sell |
68,140
-188
| -0.3% | -$129K | 0.21% | 95 |
|
|
2024
Q4 | $48M | Sell |
68,328
-6,888
| -9% | -$5.78M | 0.22% | 82 |
|
|
2024
Q3 | $79M | Buy |
75,216
+1,408
| +2% | +$1.57M | 0.36% | 52 |
|
|
2024
Q2 | $77.6M | Sell |
73,808
-146
| -0.2% | -$142K | 0.37% | 51 |
|
|
2024
Q1 | $71.1M | Sell |
73,954
-1,973
| -3% | -$1.88M | 0.35% | 54 |
|
|
2023
Q4 | $66.7M | Sell |
75,927
-487
| -0.6% | -$401K | 0.39% | 46 |
|
|
2023
Q3 | $62.9M | Sell |
76,414
-23,521
| -24% | -$18.5M | 0.41% | 44 |
|
|
2023
Q2 | $71.8M | Buy |
99,935
+10,522
| +12% | +$8.11M | 0.47% | 39 |
|
|
2023
Q1 | $73.5M | Sell |
89,413
-10,901
| -11% | -$8.22M | 0.51% | 39 |
|
|
2022
Q4 | $72.4M | Sell |
100,314
-24,893
| -20% | -$18.4M | 0.54% | 36 |
|
|
2022
Q3 | $86.3M | Buy |
125,207
+13,161
| +12% | +$8.28M | 0.67% | 29 |
|
|
2022
Q2 | $66.2M | Sell |
112,046
-41,230
| -27% | -$26.8M | 0.49% | 48 |
|
|
2022
Q1 | $107M | Sell |
153,276
-46,354
| -23% | -$29.3M | 0.63% | 27 |
|
|
2021
Q4 | $128M | Buy |
199,630
+90,971
| +84% | +$55.9M | 0.66% | 28 |
|
|
2021
Q3 | $65.8M | Buy |
108,659
+52,821
| +95% | +$32.8M | 0.36% | 64 |
|
|
2021
Q2 | $31.2M | Sell |
55,838
-27,991
| -33% | -$14.2M | 0.19% | 117 |
|
|
2021
Q1 | $39.7M | Sell |
83,829
-32,058
| -28% | -$15.6M | 0.26% | 86 |
|
|
2020
Q4 | $56M | Buy |
115,887
+11,759
| +11% | +$6.35M | 0.39% | 62 |
|
|
2020
Q3 | $58.3M | Buy |
104,128
+5,703
| +6% | +$3.46M | 0.43% | 54 |
|
|
2020
Q2 | $61.4M | Sell |
98,425
-18,817
| -16% | -$10.7M | 0.5% | 43 |
|
|
2020
Q1 | $57.2M | Sell |
117,242
-29,290
| -20% | -$12.1M | 0.58% | 35 |
|
|
2019
Q4 | $55M | Buy |
146,532
+103,589
| +241% | +$34.9M | 0.43% | 55 |
|
|
2019
Q3 | $11.9M | Sell |
42,943
-12,504
| -23% | -$3.7M | 0.1% | 185 |
|
|
2019
Q2 | $17.4M | Sell |
55,447
-76,750
| -58% | -$25.6M | 0.15% | 139 |
|
|
2019
Q1 | $54.3M | Buy |
132,197
+1,245
| +1% | +$513K | 0.5% | 53 |
|
|
2018
Q4 | $48.9M | Buy |
130,952
+35,323
| +37% | +$12.9M | 0.44% | 49 |
|
|
2018
Q3 | $38.6M | Buy |
95,629
+51,903
| +119% | +$19.8M | 0.29% | 76 |
|
|
2018
Q2 | $15.1M | Buy |
43,726
+4,003
| +10% | +$1.25M | 0.13% | 129 |
|
|
2018
Q1 | $13.7M | Sell |
39,723
-3,009
| -7% | -$1.05M | 0.13% | 123 |
|
|
2017
Q4 | $16.1M | Sell |
42,732
-1,957
| -4% | -$793K | 0.14% | 129 |
|
|
2017
Q3 | $20M | Sell |
44,689
-2,100
| -4% | -$999K | 0.18% | 110 |
|
|
2017
Q2 | $23M | Sell |
46,789
-4,682
| -9% | -$2.05M | 0.22% | 105 |
|
|
2017
Q1 | $19.9M | Sell |
51,471
-6,624
| -11% | -$2.46M | 0.2% | 101 |
|
|
2016
Q4 | $21.3M | Sell |
58,095
-8,769
| -13% | -$3.33M | 0.26% | 79 |
|
|
2016
Q3 | $26.9M | Sell |
66,864
-5,100
| -7% | -$2.05M | 0.29% | 75 |
|
|
2016
Q2 | $25.1M | Sell |
71,964
-3,100
| -4% | -$1.19M | 0.28% | 75 |
|
|
2016
Q1 | $27.1M | Sell |
75,064
-7,800
| -9% | -$3.21M | 0.3% | 67 |
|
|
2015
Q4 | $45M | Buy |
+82,864
| New | +$44.9M | 0.58% | 36 |
|
Other funds holding REGN
Skandinaviska Enskilda Banken (SEB)'s REGN Position: Q1 2026 in Review
Skandinaviska Enskilda Banken (SEB) sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 56,619 shares — an estimated $43.7M sold.
Skandinaviska Enskilda Banken (SEB) first reported a position in REGN in Q4 2015 and held it in 41 quarters. The position peaked at $128M in Q4 2021. 1,399 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Skandinaviska Enskilda Banken (SEB) reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Skandinaviska Enskilda Banken (SEB) sold 56,619 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $43.7M.
- Skandinaviska Enskilda Banken (SEB) first reported a position in Regeneron Pharmaceuticals in Q4 2015 and held it in 41 quarters.
- Skandinaviska Enskilda Banken (SEB)'s Regeneron Pharmaceuticals position peaked at $128M in Q4 2021.
- 1,399 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2026, filed 15 May 2026.